INTERNATIONAL PATENT: KADMON CORPORATION, LLC FILES APPLICATION FOR "METHODS OF TREATING CHRONIC GRAFT VERSUS HOST DISEASE WITH BELUMOSUDIL AFTER CEASING ADMINISTRATION OF RUXOLITINIB"

GENEVA, Sept. 10 -- KADMON CORPORATION, LLC (55 Corporate DriveBridgewater, New Jersey 08807) filed a patent application (PCT/US2025/017283) for "METHODS OF TREATING CHRONIC GRAFT VERSUS HOST DISEASE WITH BELUMOSUDIL AFTER CEASING ADMINISTRATION OF RUXOLITINIB" on Feb 26, 2025. With publication no. WO/2025/184133, the details related to the patent application was published on Sep 04, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): SAPRA, Rajat (c/o Sanofi, Patent Department450 Water StreetCambridge, Massachusetts 02141), SKAAR, Jeffrey (c/o Trinity Partners, LLC.230 Third AvenueWaltham, Mass...